SOLID BIOSCIENCES INC (SLDB) Stock Price, Forecast & Analysis
NASDAQ:SLDB • US83422E2046
SLDB Key Statistics, Chart & Performance
The current stock price of SLDB is 5.73 USD. In the past month the price decreased by -16.76%. In the past year, price decreased by -1.21%.
SLDB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SLDB. When comparing the yearly performance of all stocks, SLDB turns out to be only a medium performer in the overall market: it outperformed 61.91% of all stocks.
SLDB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLDB. While SLDB has a great health rating, there are worries on its profitability.
SLDB Financial Highlights
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 18.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.02% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
SLDB Forecast & Estimates
19 analysts have analysed SLDB and the average price target is 16.04 USD. This implies a price increase of 179.96% is expected in the next year compared to the current price of 5.73.
SLDB Ownership
SLDB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.75 | 397.325B | ||
| AMGN | AMGEN INC | 16.85 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.79 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.9 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.34 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.79 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.93 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLDB
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 100
Phone: 16173374680
SOLID BIOSCIENCES INC / SLDB FAQ
What does SLDB do?
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
What is the stock price of SOLID BIOSCIENCES INC today?
The current stock price of SLDB is 5.73 USD. The price increased by 0.35% in the last trading session.
What is the dividend status of SOLID BIOSCIENCES INC?
SLDB does not pay a dividend.
What is the ChartMill rating of SOLID BIOSCIENCES INC stock?
SLDB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of SLDB stock?
SOLID BIOSCIENCES INC (SLDB) has a market capitalization of 446.42M USD. This makes SLDB a Small Cap stock.
Can you provide the ownership details for SLDB stock?
You can find the ownership structure of SOLID BIOSCIENCES INC (SLDB) on the Ownership tab.
What is the outstanding short interest for SOLID BIOSCIENCES INC?
The outstanding short interest for SOLID BIOSCIENCES INC (SLDB) is 13.28% of its float.